Send us a text

Join Kennedy Schaal (CEO) and Axel Schumacher (Chief Biotechnology Officer) of Rejuve Biotech to learn how they are using cutting-edge AI and innovative drug discovery methods to improve our health and extend our lifespan.

With Ben Goertzel, Lisa Rein and Grace Robot.

#Longevity #PrecisionMedicine #AI

About Dr. Axel Schumacher:

Dr. Axel Schumacher is the Chief Biotechnology Officer of Rejuve Biotech, which combines state-of-the-art machine learning and artificial general intelligence methods with a continuously updated biomedical knowledge graph integrating human and model organism databases. He has over 25 years of R&D leadership experience in genomics, epigenetics, biomarker discovery, Bio-IT, ageing & longevity.

In 2010, Schumacher proposed the ‘epigenetic theory of aging’ a new unifying model of aging and the development of complex diseases, incorporating classical aging theories and epigenetics. His foundational work on epigenetic drift and age-related epigenetic changes in mice and humans led to the "epigenetic clock" theory of aging.

Earlier in his career, Schumacher invented the technology of ‘epigenetic microarrays’ which led to hundreds of research discoveries across the world, including the first worldwide proof of whole genome epigenetic changes in schizophrenia and bipolar disorder.

About Kennedy Schaal:

Kennedy Schaal, CEO of Rejuve Biotech is the visionary force behind Rejuve.BIO and a true pioneer in the field of longevity science. With a strong leadership track record in applied genomic research and artificial intelligence, Kennedy has earned the moniker "Fly Queen" for her groundbreaking work with Drosophila melanogaster Methuselah Flies. Her expertise in genomic selection and breeding, combined with cutting-edge AI, has positioned her as a world-leading expert in the quest for extended health and lifespan.

Kennedy's contributions to the science of longevity are not only theoretical but also practical. She is a multi-published author, sharing her insights and findings on applied genomics trials and the science of aging.

About Rejuve Biotech:

Rejuve Biotech is a partner company to Rejuve.AI and is building an innovative AI-powered drug discovery and development platform. The project is developing a translational medicine service that combines an in-house model organism population with a unique AI-based analytical platform. The platform combines state-of-the-art machine learning and artificial general intelligence methods with a continuously updated biomedical knowledge graph integrating human and model organism databases. The Rejuve Bio Flybase (fly genetics Atomspace database) and longevity drug prediction and discovery engines will be some of the first use cases of the OpenCog Hyperon AGI framework.

The Rejuve Biotech animal model of choice is the long-lived Methuselah Fly, a type of Drosophila melanogaster (fruit fly), selectively bred over hundreds of generations to live at least 5 times longer than wild-type flies. These flies offer an expedited mode for generational longevity studies and for early evaluation of potential therapy candidates — faster, less expensive, and more scalable than human or other animal models.

FOLLOW Mindplex Podcast:

WEBSITE → https://magazine.mindplex.ai/

Mindplex News → https://magazine.mindplex.ai/news/

Mindplex TWITTER → https://twitter.com/Mindplex_ai/

FACEBOOK → https://www.facebook.com/MindplexAI/

YOUTUBE → https://www.youtube.com/@mindplexpodcast/